DSGN official logo DSGN
DSGN 1-star rating from Upturn Advisory
Design Therapeutics Inc (DSGN) company logo

Design Therapeutics Inc (DSGN)

Design Therapeutics Inc (DSGN) 1-star rating from Upturn Advisory
$9.43
Last Close (24-hour delay)
Profit since last BUY26.92%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 24 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: DSGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $13.5

1 Year Target Price $13.5

Analysts Price Target For last 52 week
$13.5 Target price
52w Low $2.6
Current$9.43
52w High $10.31

Analysis of Past Performance

Type Stock
Historic Profit -68.73%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 537.17M USD
Price to earnings Ratio -
1Y Target Price 13.5
Price to earnings Ratio -
1Y Target Price 13.5
Volume (30-day avg) 3
Beta 1.64
52 Weeks Range 2.60 - 10.31
Updated Date 12/14/2025
52 Weeks Range 2.60 - 10.31
Updated Date 12/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.19

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -20.49%
Return on Equity (TTM) -29.83%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 332941228
Price to Sales(TTM) 22642.01
Enterprise Value 332941228
Price to Sales(TTM) 22642.01
Enterprise Value to Revenue 11004.35
Enterprise Value to EBITDA -0.84
Shares Outstanding 56963757
Shares Floating 26602075
Shares Outstanding 56963757
Shares Floating 26602075
Percent Insiders 35.97
Percent Institutions 58.98

About Design Therapeutics Inc

Exchange NASDAQ
Headquaters Carlsbad, CA, United States
IPO Launch date 2021-03-26
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 55
Full time employees 55

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.